- Alpha Cognition (CSE:ACOG), a biopharma stock developing treatments for neurodegenerative disorders, has received FDA approval for Zunveyl (benzgalantamine), its treatment for mild-to-moderate Alzheimer’s disease
- The Alzheimer’s disease market is expected to grow by more than six times to more than US$13 billion through this decade
- Alpha Cognition is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease and cognitive impairment with mild traumatic brain injury
- Alpha Cognition stock has added 86.05 per cent year-over-year, but is down by about 43 per cent since its initial public offering in 2021
Alpha Cognition (CSE:ACOG), a biopharma stock developing treatments for neurodegenerative disorders, has received FDA approval for Zunveyl (benzgalantamine), its treatment for mild-to-moderate Alzheimer’s disease.
Alzheimer’s disease affects more than 50 million people across the world, according to Alzheimer’s disease International, and represents a multi-billion-dollar market that is expected to grow by more than six times to more than US$13 billion through this decade.
Zunveyl differentiates itself in the marketplace by offering the same long-term memory, attention and mortality benefits as galantamine, a standard of care approved by the FDA in 2001, while minimizing its propensity to cause severe insomnia and gastrointestinal issues. According to Monday’s news release, the drug’s increased tolerability could meaningfully decrease the 55 per cent of Alzheimer’s patients that discontinue their medication after one year.
Zunveyl will be available by prescription through pharmacies across the United States in Q1 2025.
Leadership insights
“I am very excited about the approval of Zunveyl, which we believe offers better tolerability for patients with Alzheimer’s disease,” Elaine Peskind, MD, the Friends of Alzheimer’s research professor of psychiatry at the University of Washington School of Medicine. “We have always believed in the efficacy of galantamine but have been limited in its use due to tolerability issues. To now have an agent with the efficacy of galantamine, but that also offers the hope of better tolerability, will provide physicians a great option to treat patients. This advancement marks a meaningful step forward in improving the quality of life for those living with Alzheimer’s and their families. As a geriatric psychiatrist specializing in Alzheimer’s disease, I am eager to incorporate this new treatment into our practice and see the positive difference it will make.”
“The approval of Zunveyl is a pivotal moment in the fight against Alzheimer’s disease, as it is only the second oral treatment to be approved in more than a decade,” added Michael McFadden, Alpha Cognition’s chief executive officer. “Zunveyl was designed to addresses a critical need for a tolerable and effective treatment that can potentially enhance patients’ daily lives with improved long-term outcomes. We are delighted, as this represents a major breakthrough in Alzheimer’s treatment, providing hope to millions of patients, families and caregivers affected by this devastating disease.”
About Alpha Cognition
Alpha Cognition is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease and cognitive impairment with mild traumatic brain injury.
Alpha Cognition stock (CSE:ACOG) was up by as much as 17.57 per cent on the news and is trading at C$0.80 per share as of 11:32 am ET. The stock has added 86.05 per cent year-over-year, but is down by about 43 per cent since its initial public offering in 2021.
Join the discussion: Find out what everybody’s saying about this biopharma stock on the Alpha Cognition Inc. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: Adobe Stock)